Market Overview:
The global zoster vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of shingles, increasing demand for zoster vaccines in developed countries, and growing awareness about the benefits of zoster vaccines. However, the high cost of zoster vaccines may restrain the growth of this market during the forecast period. On the basis of type, live attenuated and recombinant are two major types of zoster vaccine available in the market.
Product Definition:
Zoster vaccine is a vaccine used to prevent zoster, also known as shingles. Zoster is a viral infection that results in a painful rash. The zoster vaccine is recommended for adults over 60 years old, and for people who have weakened immune systems.
Live:
Live, also known as attenuated vaccine strain, is a type of vaccine that is made from the sap or juice of a virus. The virus can be either weakened or killed by heat treatment (pasteurization) and then it can be used to infect people to produce antibodies against the disease. In order for these vaccines to work best, they must match the particular disease that we are trying to protect against.
Recombinant:
Recombinant DNA (rDNA) is a man-made sequence that replicates in a similar way to the natural DNA. It is used as a vector for the production of various therapeutic and diagnostic proteins. rDNA can be used as an expression vector for the synthesis of any protein, including immunoglobulin, insulin, and growth hormone.
Application Insights:
The other application segment includes the use of zoster vaccine for treatment and prevention of diseases. The government sector accounted for a major share in the global market due to increasing expenditure on immunization programs against various diseases, including chickenpox.
In 2015, the private sector was estimated to be the largest consumer of vaccines with regard to Zostavax usage. This is because many companies offer financial Incentive Programmes (IPs) that encourage employees who have not been exposed to Zostavax but have had close contact with someone who has been fully vaccinated against chickenpox at work or school settings. These incentives help offset some of the costs associated with vaccination and also provide an opportunity for additional profit generation through cost savings achieved through reduced medical expenditure as well as avoidable visits/hospital admissions owing to illness in case no IP exists between employer and employee regarding this particular immunization program being covered by insurance or not.
Regional Analysis:
North America dominated the global market in 2017. The presence of a strong research base and biopharmaceutical industry is expected to drive the development of zoster vaccines in this region. Moreover, increasing incidence of shingles among older adults is further anticipated to boost demand for these vaccines over the forecast period.
The U.S., which was at the forefront of North America, accounted for more than 80% share owing to high prevalence rates associated with this condition coupled with government initiatives favoring vaccine development activities towards ZOSTER virus infection prevention & control programs globally as well as domestically within North American countries such as Mexico and Canada are some factors attributing towards its largest share observed within Latin America region during same year (2017).
Asia Pacific witnessed significant growth from 2018 to 2030 due to rising awareness about shingles vaccination programs along with growing target population especially in developing economies such as China & India that account for majority shares within Asia Pacific regional market including Australia, Japan.
Growth Factors:
- Increasing incidence of shingles across the globe
- Growing awareness about the benefits of zoster vaccine among people
- Rising demand for zoster vaccine in developed countries
- Technological advancements in the manufacturing of zoster vaccine
- Availability of government funding for purchase of zoster vaccines
Scope Of The Report
Report Attributes
Report Details
Report Title
Zoster Vaccine Market Research Report
By Type
Live, Recombinant
By Application
Government Institution, Private Sector, Other
By Companies
GSK, Merck, Sanofi Pasteur
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Zoster Vaccine Market Report Segments:
The global Zoster Vaccine market is segmented on the basis of:
Types
Live, Recombinant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Government Institution, Private Sector, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Merck
- Sanofi Pasteur
Highlights of The Zoster Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Live
- Recombinant
- By Application:
- Government Institution
- Private Sector
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Zoster Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Zoster vaccine is a vaccine that helps protect people from shingles. It is made from the same virus that causes chickenpox, but it has been modified so it does not cause the full chickenpox infection. Zoster vaccine helps prevent shingles (a painful rash caused by the herpes zoster virus) in people who have had chickenpox.
Some of the major players in the zoster vaccine market are GSK, Merck, Sanofi Pasteur.
The zoster vaccine market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Zoster Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Zoster Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Zoster Vaccine Market - Supply Chain
4.5. Global Zoster Vaccine Market Forecast
4.5.1. Zoster Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Zoster Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Zoster Vaccine Market Absolute $ Opportunity
5. Global Zoster Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Zoster Vaccine Market Size and Volume Forecast by Type
5.3.1. Live
5.3.2. Recombinant
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Zoster Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Zoster Vaccine Market Size and Volume Forecast by Application
6.3.1. Government Institution
6.3.2. Private Sector
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Zoster Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Zoster Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Zoster Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Zoster Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Zoster Vaccine Demand Share Forecast, 2019-2026
9. North America Zoster Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Zoster Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Zoster Vaccine Market Size and Volume Forecast by Application
9.4.1. Government Institution
9.4.2. Private Sector
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Zoster Vaccine Market Size and Volume Forecast by Type
9.7.1. Live
9.7.2. Recombinant
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Zoster Vaccine Demand Share Forecast, 2019-2026
10. Latin America Zoster Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Zoster Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Zoster Vaccine Market Size and Volume Forecast by Application
10.4.1. Government Institution
10.4.2. Private Sector
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Zoster Vaccine Market Size and Volume Forecast by Type
10.7.1. Live
10.7.2. Recombinant
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Zoster Vaccine Demand Share Forecast, 2019-2026
11. Europe Zoster Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Zoster Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Zoster Vaccine Market Size and Volume Forecast by Application
11.4.1. Government Institution
11.4.2. Private Sector
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Zoster Vaccine Market Size and Volume Forecast by Type
11.7.1. Live
11.7.2. Recombinant
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Zoster Vaccine Demand Share, 2019-2026
12. Asia Pacific Zoster Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Zoster Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Zoster Vaccine Market Size and Volume Forecast by Application
12.4.1. Government Institution
12.4.2. Private Sector
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Zoster Vaccine Market Size and Volume Forecast by Type
12.7.1. Live
12.7.2. Recombinant
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Zoster Vaccine Demand Share, 2019-2026
13. Middle East & Africa Zoster Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Zoster Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Zoster Vaccine Market Size and Volume Forecast by Application
13.4.1. Government Institution
13.4.2. Private Sector
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Zoster Vaccine Market Size and Volume Forecast by Type
13.7.1. Live
13.7.2. Recombinant
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Zoster Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Zoster Vaccine Market: Market Share Analysis
14.2. Zoster Vaccine Distributors and Customers
14.3. Zoster Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GSK
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi Pasteur
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
